We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
CASR and ADH1: Integrating Biology and Genetic Screening
Therapeutic Options for ADH1 and Hypoparathyroidism
Emerging Therapeutics in ADH1: Progress in Precision Medicine
5 Things You Need to Know About Epilepsy & Depression
Heidi M. Munger Clary, MD, MPH
Jay Salpekar, MD, FANPA
Early Recognition and Diagnosis of Castleman Disease
Sanam Loghavi, MD
Razelle Kurzrock, MD, FACP
Improving Outcomes in Patients with RVO: Tailoring Treatment
Carl Danzig, MD
Arshad M. Khanani, MD, MA
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
Scott Kahan, MD, MPH
Ken Fujioka, MD
Carol Wysham, MD
Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)
Annie Levesque, MD, MSc
Ethan A. Cowan, MD
Postpartum Depression: A Significant Burden and a Novel Approach to Treatment
Lee Shulman MD, FACOG, FACMG
Kristina Deligiannidis, MD
Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?
Stefan D. Anker, MD, PhD
John Cleland, MD
Piotr Ponikowski, MD, PhD, FESC, FHFA
New Frontiers in Anticoagulation: Factor XI/XIa Inhibitors
Christopher B. Granger, MD
Manesh R. Patel, MD
M. Cecilia Bahit, MD
Elaine Hylek, MD, MPH
The DOAC Revolution: What Have We Learned?
While the DOAC Revolution Has Occurred, 40-50% of Patients Remain Untreated... Why?
While DOACs are Good for Some Things, They Are Not for Everyone
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education